Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors
- 6.6k Downloads
Ankylosing spondylitis (AS) is unique in its pathology where inflammation commences at the entheses before progressing to an osteoproliferative phenotype generating excessive bone formation that can result in joint fusion. The underlying mechanisms of this progression are poorly understood. Recent work has suggested that changes in Wnt signalling, a key bone regulatory pathway, may contribute to joint ankylosis in AS. Using the proteoglycan-induced spondylitis (PGISp) mouse model which displays spondylitis and eventual joint fusion following an initial inflammatory stimulus, we have characterised the structural and molecular changes that underlie disease progression.
PGISp mice were characterised 12 weeks after initiation of inflammation using histology, immunohistochemistry (IHC) and expression profiling.
Inflammation initiated at the periphery of the intervertebral discs progressing to disc destruction followed by massively excessive cartilage and bone matrix formation, as demonstrated by toluidine blue staining and IHC for collagen type I and osteocalcin, leading to syndesmophyte formation. Expression levels of DKK1 and SOST, Wnt signalling inhibitors highly expressed in joints, were reduced by 49% and 63% respectively in the spine PGISp compared with control mice (P < 0.05) with SOST inhibition confirmed by IHC. Microarray profiling showed genes involved in inflammation and immune-regulation were altered. Further, a number of genes specifically involved in bone regulation including other members of the Wnt pathway were also dysregulated.
This study implicates the Wnt pathway as a likely mediator of the mechanism by which inflammation induces bony ankylosis in spondyloarthritis, raising the potential that therapies targeting this pathway may be effective in preventing this process.
KeywordsGene Ontology Ankylose Spondylitis Spondylitis Nucleus Pulposus Annulus Fibrosus
collagen type I
gene set analysis
glycogen synthase kinase
haematoxylin and eosin
human leukocyte antigen
low-density lipoprotein receptor-related protein
magnetic resonance imaging
proteoglycan-induced spondylitis mouse
quantitative real-time reverse-transcription PCR
tumour necrosis factor
variance stabilization transformation.
Ankylosing spondylitis (AS) displays a unique pathology in its progression from an initial inflammatory phase to an osteoproliferative/ankylosing phase, which can result in joint fusion . The inflammatory phase has similarities with other inflammatory arthopathies such as rheumatoid arthritis (RA) with high levels of pro-inflammatory cytokine production and joint damage through osteoclast activity . However, whereas the synovitis of RA is associated with joint erosion, while there is initial erosion in AS, the joint disease is primarily characterised by osteoproliferation and consequent ankylosis. There is considerable debate as to how the inflammation and osteoproliferation are linked, including whether the inflammation directly leads to the osteoproliferation, ceases before induction of bone formation, or whether the inflammatory and osteoproliferative phases are completely uncoupled . The initial inflammation occurs in axial entheses, such as the spinal and sacroiliac ligament attachments, or sites of attachment of the annulus fibrosus outer fibres of the intervertebral discs (IVDs), progressing to osteoproliferation, squaring of the vertebrae and formation of syndesmophytes from the vertebral corners, which can eventually bridge leading to ankylosis. How this inflammation is initiated and how it progresses through to bone formation and eventual ankylosis is poorly understood.
A number of informative studies have characterised disease progression using radiography and magnetic resonance imaging (MRI) [4, 5] but such modalities can only inform on gross structural changes. Elucidation of the cellular and molecular changes that contribute to disease progression requires tissue samples from disease sites. However, the difficulties in obtaining biopsy at axial skeletal sites means very few informative clinical samples are available. Animal models are thus a good option for examining detailed events occurring at axial disease sites. Although a number of animal models present some of the features similar to those seen in human disease, no mouse model as yet has proven to be a good model in which to study the progression from inflammation to ankylosis in the axial skeleton. Transgenic rats over-expressing the HLA-B27 and human β2-microglobulin have been shown to spontaneously display gut disease and peripheral and axial inflammatory arthritis , but ankylosis was only seen in rats with increased expression of β2-microglobulin, which coincided with reduced gut disease and unfolded protein response . Two mouse models over-expressing TNF-α, either through a transgenic approach (hTNFtg) , or through increasing TNF mRNA stability by deleting the 3' ARE regulatory elements (TNFΔARE), show systemic inflammation, gut disease and sacroiliitis but do not spontaneously develop ankylosis. Several mouse models have exhibited spontaneous ankylosing enthesopathy (ANKENT), including C57BL/10  and DBA/1  mice, but this has been limited to peripheral joints. The only inducible mouse model demonstrating axial ankylosis as well as a strong immune component is the proteoglycan (PG)-induced spondylitis model (PGISp). Disease is induced by injections of a human cartilage PG extract, and mimics many of the clinical features of the human disease, particularly axial inflammation and ankylosis stemming from an initial inflammatory stimulus [12, 13].
The Wnt pathway has been established as a key regulatory pathway for the bone-forming cells, osteoblasts, stimulating both osteoblast proliferation and maturation . During canonical Wnt signalling in bone, soluble Wnts bind to their Frizzled (Fzd) receptors and LRP4/5/6 co-receptors in a ternary complex at the cell surface, resulting in glycogen synthase kinase 3 (GSK-3β) inhibition, permitting β-catenin (β-cat) accumulation. Accumulated β-cat translocates into the nucleus and activates target gene transcription. In the absence of signalling, β-cat is phosphorylated, mainly by GSK3β, resulting in β-cat ubiquitination and proteasome-mediated degradation. In bone, Dickkopf-1 (DKK-1), sclerostin (SOST) and the secreted Fzd-related proteins are key inhibitors of the Wnt pathway, binding either to LRP4/5/6 inhibiting its interaction with the Wnt-Fzd complex, or associating with Wnts, blocking their participation in the pathway . A number of recent papers have demonstrated changes in SOST and DKK1 in the hTNFtg mouse model and in AS patients, suggesting a role for this pathway in the osteoproliferation characteristic of AS [15, 16, 17].
We therefore sought to investigate whether SOST and DKK1 are dysregulated in the PGISp model, given it is a good experimental model for assessing cellular and molecular events involved in severe axial osteoproliferation and ankylosis as seen in AS. In the studies described here we have undertaken an in-depth morphological and molecular study to examine the nature of the spondylitis and identified molecular changes that might contribute to the joint changes in the PGISp model. As well as identifying changes in matrix component expression levels that underlie the excessive bone matrix formation seen, we also observed decreases in Wnt-signalling inhibitors that might promote increased bone formation contributing to ankylosis.
Materials and methods
The PGISp model has been described previously [12, 13]. For the studies described here the model was established on the IL4-/- background due to the reported increased penetrance . Briefly, three-month old female mice were injected with 2 mg of human cartilage extract equivalent to 100 μg of PG core protein, together with 2 mg dimethyl dioctadecyl ammoniumbromide (Sigma, St. Louis, MO, USA). Three month-old female mice were injected three times at day 0, 21 and 42. Mice were collected at week 12 for the subsequent analyses described below. All mouse studies were carried out under the approval of the University of Queensland Animal Ethics Committee. For the histology studies four control and seven PGISp mice were analysed. For the gene expression analyses, seven control and six PGISP mice were analysed and of these, four control and four PGISp mice were used for the microarray study.
Skeletons were collected and fixed in neutral buffered formalin and decalcified in 14% ethylenediaminetetraacetic acid (EDTA). Sections were stained with H&E or toluidine blue according to standard protocols. Gruber's stain has been described previously  with a combination of Weigert's haematoxylin, alcian blue and picrosirius red producing distinctive staining of collagen (red), PG (blue) and the cellular elements of the IVD. Severity of vertebral joint disease was scored as described previously ; score 1, enthesitis, inflammatory cell accumulation around the IVD and/or infiltration of the annulus fibrosus; score 2, < 50% absorption/erosion of the IVD; score 3, essentially complete resorption (> 50%) of the IVD; score 4, cartilaginous/bony ankylosis.
RNA extraction and microarray analysis
Whole spines from control and PGISp mice were flash-frozen on collection and stored at -80°C. Due to the requirements to preserve RNA integrity it was not possible to assess the activity of arthritis in the spines before RNA extraction, but only mice displaying severe peripheral arthritis were selected. RNA was extracted using Trizol (Life Technologies, Mulgrave, Victoria, Australia) as per the manufacturer's instructions as described previously , then cleaned using RNAeasy columns (Qiagen, Doncaster, Victoria, Australia). For microarray analysis cRNA was generated from 500 ng total RNA using the Illumina TotalPrep cRNA Amplification Kit and hybridised to Mouse Ref-8 Expression BeadChips (Illumina, San Diego, CA, USA). Array data were processed as described previously  using the Illumina GenomeStudio software and then transformed by variance stabilization transformation (VST) and normalized by robust spline normalization using Lumi . Gene expression analysis was performed in BRB-ArrayTools . Differentially expressed genes were identified by unpaired t-test with multivariate permutation correction. These data have been uploaded to the NCI GEO database [GEO: GSE41039].
Gene Ontology analysis
The evaluation of the gene ontology (GO) classes that are differentially expressed between control and affected bones was performed using a functional class scoring analysis as described previously . For each gene in a GO class, the P-value for comparing control and affected samples was computed. The set of P-values for a class was summarised by two summary statistics: (i) The log summary (LS) is the average of the log P-values for the genes in that class and (ii) the Kolmogorov-Smirnov summary (KS) is the Kolmogorov-Smirnov statistic computed on the P-values for the genes in that class. The statistical significance of the GO class containing n genes represented on the array was evaluated by computing the empirical distribution of these summary statistics in random samples of n genes. Functional class scoring is a more powerful method of identifying differentially expressed gene classes than the more common over-representation analysis or annotation of gene lists based on individually analysed genes. Efron-Tibshirani's gene set analysis (GSA) was also used, which uses maxmean statistics for assessing the significance of predefined gene sets and generates a direction of significant expression changes. GO analysis was performed using BRB-ArrayTools.
To examine a possible shift towards osteoblastic activity in the affected spine we generated an osteoblast gene list comprised of well-characterised genes known to be expressed in osteoblasts, which is not available in the standard GO analysis. The genes incorporated in this list were Sp7, Ifitm5, Sost, Ostn, Runx2, Osteocalcin (Bglap), Rankl (Tnfrsf11b), Rank (Tnfsf11), Dmp1, Phex, Alkaline phosphatase (Alpl), Col1a1, Ibsp, Spp1, Pthr1 and Sparc.
Both Sost and Dkk1 were expressed at background levels in the microarray study so we utilised quantitative real-time reverse-transcription PCR (qPCR) to accurately measure their transcription levels. RNA (1000 ng) was reverse-transcribed using both oligo-dT primers and random hexamers using the Bioline cDNA Synthesis Kit (Bioline, Alexandria, NSW, Australia) and expression was measured using Taqman assays (Life Technologies, Mulgrave, Victoria, Australia) for Sost and Dkk1 and b-Actin was used as a housekeeping gene to normalise expression.
Comparison of control and PGISP joints for histological scoring, expression levels of Sost and Dkk1 and SOST IHC were analysed using GraphPad Prism 5 (GraphPad Software Inc, La Jolla, CA, USA), using non-parametric Mann-Whitney tests. Data are expressed at the mean ± SD.
Inflammation followed a similar time course to that previously described for this model . Initial peripheral inflammation in the knees and ankles, as well as the forelimbs, was evident after the second PG injection and peripheral inflammation increased over a further 8-week period before maximising at 12 weeks after the start date (data not shown). Our focus for this study was on the spondylitis, previously described in this model . Mice were analysed 12 weeks (day 84) after the first PG injection (day 0) when both axial and peripheral disease was well-established.
Gene ontology (GO) analysis of genes differentially expressed in control and proteoglycan-induced spondylitis (PGISp) mouse spines
Number of genes
LS permutation P-value
KS permutation P-value
Efron-Tibshirani's GSA test P-value
immune effector process
< 0.005 (+)
immune system process
myeloid leukocyte mediated immunity
regulation of immune system process
positive regulation of immune system process
< 0.005 (+)
collagen metabolic process
Inflammation and osteoblast-associated genes over-expressed in proteoglycan-induced spondylitis (PGISp) spines
Fold change PGISp/Control
Matrix metallopeptidase 3
Matrix metallopeptidase 13
Tissue inhibitor of metalloproteinase 1
Interleukin 1, beta
Interleukin 1 receptor, type II
interleukin 28 receptor alpha
Signal transducer and activator of transcription 1
Signal transducer and activator of transcription 3
Collagen Type I
Collagen Type III
We also looked for changes indicative of osteoproliferative activity. We generated an osteoblast gene list composed of well-characterised osteoblast-associated genes and used it to undertake a GO analysis. This showed a highly significant upregulation in this gene set (Table 1) with Col1a1 (2.5-fold), bone sialoprotein (Ibsp) (2.6-fold), osteonectin (Sparc), (1.6-fold) and osteocalcin (BGlap1) (1.5-fold) all upregulated (all P < 0.03) (Table 2).
The PGISp model is a well-established mouse model of arthritis that exhibits both axial and peripheral inflammation  and has previously been presented as a model of spondylitis . This further characterisation of axial disease pathology and underlying molecular changes in the Wnt signalling pathway further establish PGISp as a good model of the bone formation arising from joint inflammation typical of AS.
Axial disease in the PGISp mice was initiated with entheseal inflammation at the periphery of the vertebral and sacral joints. These inflammatory cells infiltrated the joint intervertebral area generating an invasive pannus, which destroys the IVD. This is then followed by proliferation of mesenchymal cells and deposition of a collagen/proteoglycan-rich matrix, which can eventually mineralise leading to ankylosis. Given this is the typical disease progression in AS , these observations establish the PGISp model as highly appropriate for investigation of AS aetiology. Initial inflammation occurs in axial insertion sites, such as the spinal and sacroiliac ligament attachments or sites of attachment of the outer fibres of the annulus fibrosus of the anterior vertebral disc. This initial enthesitis progresses and often a destructive spondylodiscitis is seen [30, 31], as well as extensive cartilage loss preceding the pathological bone formation that underlies the joint fusion seen in advanced cases.
Whether the initial inflammation directly links to the subsequent osteoproliferative stages is subject to significant debate. There is considerable evidence that syndesmophytes develop at sites where previous inflammation has been observed . Exactly how inflammation and bone formation are linked is not clear, with studies demonstrating that inhibition of inflammation does not affect radiographic progression in either human  or mouse  studies. However, it has also been shown in longitudinal human imaging studies that the presence of inflammatory lesions can predict the future development of syndesmophytes . Our present study indicates the damage is certainly triggered by an initial inflammatory insult but there is little evidence of inflammatory cells remaining at sites where an extensive osteoproliferative response has occurred.
The study described here has further detailed the structural changes occurring at axial disease sites in the PGISp model and identified some of the molecular mechanisms that contribute to the disease process. IVD destruction follows the initial inflammation with extensive cell proliferation and excessive tissue formation then becoming evident. The nucleus pulposus is PG-rich, whereas the annulus fibrosus stains less strongly . The matrix laid down in place of the destroyed disc in this model shows a different makeup, being rich in unmineralised PG, except at the periphery where collagen appears to comprise a significant component of the matrix. At this point, staining for unmineralised PG is negative, which might indicate a transition from a fibrocartilage-based matrix to immature bone. OCN staining is only present at the outer periphery of this matrix, indicating that this matrix has not yet developed into mature bone. It is clear that the model exhibits a strong anabolic response to the initial inflammatory insult.
We also sought to investigate the molecular changes underlying the progression through inflammation to bone formation using whole-genome expression analysis. Inflammatory as well as both matrix catabolic and anabolic pathways were altered. Elements of both the IL-1 and TNF pathways were upregulated. Both these pathways have been associated with AS through genetic studies [36, 37]. IL28ra has been associated with psoriasis, a condition frequently co-existing in AS patients . Stat1 and Stat3 mediate TH1 and IL-17-associated signalling respectively, with both cell types thought to play a role in the PGISp model [39, 40] and have been implicated in SpA [41, 42]. Elevated expression in these genes might reflect the increased TH1 and IL-17-expressing cell activity seen in these mice. STAT3 has also been shown to be associated with human AS . These molecular disease patterns further support that the PGISp model replicates not only cellular changes in AS but also but also molecular patterns as well as inflammation polarization.
Mirroring the destructive nature of the early disease, stage changes in matrix remodelling factor expression levels were seen. MMP3, a stromelysin, and MMP13, a collagenase, key enzymes in extracellular matrix remodelling, which have both been shown to be elevated in AS as well as animal models [34, 44, 45], were both strongly upregulated. The strong matrix formation response was also reflected with marked upregulation of the key bone matrix components Col1, bone sialoprotein and OCN, as well as a number of other extracellular matrix-associated genes.
These gene expression changes mirror the tissue alterations seen in the joint but of further interest, particularly from a potential therapeutic point of view, are the molecules driving these tissue changes. The Wnt signalling pathway has been established as a key regulatory pathway for the bone-forming cells, osteoblasts, with SOST and DKK1 key inhibitors of Wnt signalling that are either specific to, or highly enriched in cells of the osteoblast lineage, respectively . Reduced DKK-1  and SOST  levels have been reported in AS patients. Blockade of DKK-1 has also been shown to drive ankylosis in a TNF-over-expressing mouse model of spondylitis . Our data support this proposed elevated Wnt signalling in spondylitis with markedly decreased levels of the Wnt inhibitors DKK1 and SOST, the first such demonstration in a mouse model of SpA or AS.
This study has demonstrated dysregulation of Wnt signalling in a mouse model of AS displaying excessive tissue formation, underlying syndesmophyte formation and ankylosis. It is likely in part that this dysregulation contributes to the osteoproliferation and supports targeting Wnt signalling therapeutically in AS. However, the key molecule(s) controlling the switch from inflammation to bone formation still require elucidation. Such molecules could provide excellent targets to develop targeted drugs to control the currently untreatable excessive bone formation leading to debilitating joint fusion.
This study was supported by Australian National Health and Medical Research Council (NHMRC) grant #APP1006450. ARP is supported by NHMRC Career Development Fellowship #519744. GPT is supported by the Lions Medical Research Foundation Senior Fellowship. MAB is supported by NHMRC Principal Research Fellowship #455836. TTG is supported by NIH/NIAMS grant R01 AR040310. We thank the staff at the Biological Research Facility at Princess Alexandra Hospital for technical support and animal care.
- 1.Ronneberger M, Schett G: Pathophysiology of Spondyloarthritis. Current Rheumatology Reports. 2011, 1-5.Google Scholar
- 4.Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RG: Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 2009, 60: 93-102. 10.1002/art.24132.CrossRefPubMedGoogle Scholar
- 5.Pedersen SJ, Sørensen IJ, Lambert RGW, Hermann K-GA, Garnero P, Johansen JS, Madsen OR, Hansen A, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen KH, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Østergaard M: Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum. 2011, 63: 3789-3800. 10.1002/art.30627.CrossRefPubMedGoogle Scholar
- 7.Tran TM, Dorris ML, Satumtira N, Richardson JA, Hammer RE, Shang J, Taurog JD: Additional human beta-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum. 2006, 54: 1317-1327. 10.1002/art.21740.CrossRefPubMedGoogle Scholar
- 16.Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G: Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine. 2007, 13: 156-163. 10.1038/nm1538.CrossRefPubMedGoogle Scholar
- 20.Chang MK, Raggatt L-J, Alexander KA, Kuliwaba JS, Fazzalari NL, Schroder K, Maylin ER, Ripoll VM, Hume DA, Pettit AR: Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. The J Immunol. 2008, 181: 1232-1244.CrossRefPubMedGoogle Scholar
- 26.Pimentel-Santos F, Ligeiro D, Matos M, Mourao A, Costa J, Santos H, Barcelos A, Godinho F, Pinto P, Cruz M, Fonseca J, Guedes-Pinto H, Branco J, Brown M, Thomas G: Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects. Arthritis Res Ther. 2011, 13: R57-10.1186/ar3309.PubMedCentralCrossRefPubMedGoogle Scholar
- 32.van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J: Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008, 58: 3063-3070. 10.1002/art.23901.CrossRefPubMedGoogle Scholar
- 34.Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D: Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 2007, 56: 1846-1853. 10.1002/art.22589.CrossRefPubMedGoogle Scholar
- 36.Sims A-M, Timms AE, Bruges-Armas J, Burgos-Vargas R, Chou C-T, Doan T, Dowling A, Fialho RN, Gergely P, Gladman DD, Inman R, Kauppi M, Kaarela K, Laiho K, Maksymowych W, Pointon JJ, Rahman P, Reveille JD, Sorrentino R, Tuomilehto J, Vargas-Alarcon G, Wordsworth BP, Xu H, Brown MA, International Genetics of Ankylosing Spondylitis: Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis. 2008, 67: 1305-1309.CrossRefPubMedGoogle Scholar
- 37.Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Opperman U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianis L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P, Morgan A, Marzo-Ortega H, Bowness P, Gaffney K, et al: Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011, 43: 761-767. 10.1038/ng.873.PubMedCentralCrossRefPubMedGoogle Scholar
- 38.Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C, Bergboer JG, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Cork MJ, Corvin A, Deloukas P, Dilthey A, Duncanson A, Edkins S, Estivill X, Fitzgerald O, Freeman C, Giardina E, Gray E, Hofer A, Huffmeier U, Hunt SE, Irvine AD, Jankowski J, et al: A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010, 42: 985-990. 10.1038/ng.694.PubMedCentralCrossRefPubMedGoogle Scholar
- 40.Boldizsar F, Tarjanyi O, Nemeth P, Mikecz K, Glant TT: Th1/Th17 polarization and acquisition of an arthritogenic phenotype in arthritis-susceptible BALB/c, but not in MHC-matched, arthritis-resistant DBA/2 mice. Int Immunol. 2009, 21: 511-522. 10.1093/intimm/dxp018.PubMedCentralCrossRefPubMedGoogle Scholar
- 42.Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, Weedon H, Street S, Thomas R, Thomas GP, Brown MA: Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012, 64: 1420-1429. 10.1002/art.33507.CrossRefPubMedGoogle Scholar
- 44.Chen C-H, Lin K-C, Yu DTY, Yang C, Huang F, Chen H-A, Liang T-H, Liao H-T, Tsai C-Y, Wei JCC, Chou C-T: Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology. 2006, 45: 414-420. 10.1093/rheumatology/kei208.CrossRefPubMedGoogle Scholar
- 46.Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G: Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009, 60: 3257-3262. 10.1002/art.24888.CrossRefPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.